| __timestamp | Ionis Pharmaceuticals, Inc. | Soleno Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 20140000 | 2917513 |
| Thursday, January 1, 2015 | 37173000 | 7878291 |
| Friday, January 1, 2016 | 48616000 | 8366794 |
| Sunday, January 1, 2017 | 108488000 | 6610381 |
| Monday, January 1, 2018 | 244622000 | 6556000 |
| Tuesday, January 1, 2019 | 287000000 | 6930000 |
| Wednesday, January 1, 2020 | 354000000 | 8758000 |
| Friday, January 1, 2021 | 186000000 | 10806000 |
| Saturday, January 1, 2022 | 151000000 | 9844000 |
| Sunday, January 1, 2023 | 232600000 | 13481000 |
Igniting the spark of knowledge
In the ever-evolving landscape of biotechnology, operational efficiency is paramount. Over the past decade, Ionis Pharmaceuticals and Soleno Therapeutics have demonstrated contrasting approaches to managing Selling, General, and Administrative (SG&A) expenses. Ionis Pharmaceuticals, a leader in RNA-targeted therapeutics, has seen its SG&A expenses grow by over 1,000% from 2014 to 2023, peaking in 2020. This reflects their aggressive expansion and investment in infrastructure. In contrast, Soleno Therapeutics, focusing on rare diseases, maintained a more conservative growth in SG&A, with a 360% increase over the same period. This strategic restraint highlights their focus on niche markets. The data reveals a fascinating narrative of two companies navigating the complexities of the biotech sector, each with its unique strategy. As the industry continues to evolve, these insights offer a glimpse into the financial strategies that drive innovation and growth.
Who Optimizes SG&A Costs Better? Regeneron Pharmaceuticals, Inc. or Ionis Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for argenx SE and Soleno Therapeutics, Inc.
Intra-Cellular Therapies, Inc. vs Ionis Pharmaceuticals, Inc.: SG&A Expense Trends
Insmed Incorporated or Ionis Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Cost Management Insights: SG&A Expenses for Sarepta Therapeutics, Inc. and Ionis Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Exelixis, Inc. and Ionis Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: Ionis Pharmaceuticals, Inc. vs Bausch Health Companies Inc.
Selling, General, and Administrative Costs: Ionis Pharmaceuticals, Inc. vs Mesoblast Limited
Operational Costs Compared: SG&A Analysis of Alpine Immune Sciences, Inc. and Soleno Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for MorphoSys AG and Soleno Therapeutics, Inc.
Soleno Therapeutics, Inc. vs Dynavax Technologies Corporation: SG&A Expense Trends
Comparing SG&A Expenses: Soleno Therapeutics, Inc. vs MiMedx Group, Inc. Trends and Insights